| Name | Title | Contact Details |
|---|
Libra Therapeutics is focused on developing novel disease-modifying therapeutics that can restore the cellular balance disrupted in neurodegenerative diseases.
We are a biopharmaceutical company specializing in the development of novel therapeutics to treat rare metabolic diseases. Our lead product candidate is INZ-701, an enzyme replacement therapy (ERT) in the early stages of clinical development for the potential treatment of patients with a variety of calcification disorders linked primarily to mutations in the ENPP1 and ABCC6 genes, or ENPP1 Deficiency and ABCC6 Deficiency respectively. We have demonstrated proof of concept with INZ-701 in both GACI and ARHR2 two phenotypes of ENPP1 Deficiency.
Kai Pharmaceuticals is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
William Gallagher Associates is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.